UCB maintained by Merrill Lynch at buy

UCB was maintained by Merrill Lynch analyst Erica Whittaker at a buy rating and a price target of €42.00 per share ahead of its earnings report due to be released July 27. Merrill expects near-term news flow for UCB's Crohn's drug Keppra and seizure drug Cimzia will drive interest in the stock. UCB shares Wednesday gained €0.03, or 0.07%, to €40.20 on volume of 301,475 shares versus the three-month running average of 238,350 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.